Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adobe Systems Inc (ADBE) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Adobe Systems IncTrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Adobe Systems Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Adobe Systems Inc trades at $261.03 (market cap $108.50B), while Regeneron Pharmaceuticals Inc trades at $796.39 (market cap $83.19B). The key difference: Adobe Systems Inc is the larger of the two by market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Adobe Systems Inc pays none. Which is the better fit depends on your goals.

ADBEREGN
Market Cap
$108.50B$83.19B
Volume
5,187,646
Sector
TechnologyHealth
52-Week High
$367.46$812.27
52-Week Low
$193.41$555.51
Enterprise Value
$109.94B$77.90B
Dividend Yield
0.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adobe Systems Inc

Adobe (ADBE) trades at $272.96, up 2.92% with strong technical momentum above key support at $270. The company demonstrates robust fundamentals with 2025 revenue of $23.77B and net income of $7.13B, maintaining exceptional profitability with 89.4% gross margins. Recent earnings beats and accelerating revenue growth contrast with mixed sentiment amid AI competition concerns and CEO transition uncertainty.

ADBE presents a compelling value proposition trading below analyst consensus targets with strong cash flow generation, though faces headwinds from AI disruption fears and sector volatility. The stock's current valuation at 15.62 P/E offers potential upside if execution continues, but requires monitoring of competitive threats and leadership stability.

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.

Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Adobe Systems Inc

Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.

Read more on ADBE

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN